Pfizer Inc. (PFE) 2024 10-K Earnings Analysis
Pfizer Inc.2024 Earnings Analysis
70/100
Pfizer's FY2024 10-K captures the post-Covid normalization year: revenue of $63.6B produced $8.0B net income at 12.5% net margin — a sharp step down from the FY2022 peak ($100B rev, $31B NI) as Comirnaty (COVID-19 vaccine) and Paxlovid (COVID antiviral) revenue contracted dramatically. Gross margin of 71.9% and OCF of $12.7B show the underlying non-Covid business remains profitable; FCF of $9.8B at 15.4% margin is now the baseline. The $43B Seagen acquisition (closed Dec 2023) adds oncology antibody-drug conjugates (ADCs); integration + synergy realization is the primary FY2025-26 thesis test. Per the available fetch coverage, the FY2024 10-K Risk Factors excerpt is not cached locally; this report relies on verified financial data plus MD&A content.
Filing analysis
Pfizer Inc. 2024 10-K Analysis
This page reads Pfizer Inc.'s 2024 10-K annual report through the EarningsMoat framework: earnings quality, economic moat strength, capital allocation, and key risks. The current overall score is 70/100, or grade C.
PFE Earnings Quality
The earnings-quality module scores 74/100, with Gross Margin: 71.9%, CF/Net Income: 1.59x. The core question is whether reported profit is backed by operating cash flow and recurring business economics. See the earnings quality analysis guide.
PFE Economic Moat Analysis
The moat-strength module scores 76/100, with Oncology via Seagen: New pillar, Vaccine Franchise: Prevnar + Covid. The test is whether the advantage can protect returns after competitors react. Read the economic moat analysis guide.
PFE Free Cash Flow vs Net Income
CF/Net Income: 1.59x is the fastest read on whether accounting earnings turn into cash. The capital-allocation module scores 68/100. For the diagnostic, start with cash flow vs net income.
PFE Key Risks from the Annual Report
The risk module scores 60/100, with Seagen Integration Execution: Multi-year test, Eliquis Patent: 2028+. The goal is to separate ordinary disclosure from risks that can change margins, cash flow, leverage, or the moat itself.
Is PFE a High Quality Earnings Stock?
Based on this 2024 filing, PFE needs a closer read before it qualifies as a high-quality earnings candidate: the overall grade is C, and the earnings-quality score is 74/100. This is a research screen, not investment advice.
Read the report first
Understand Pfizer Inc. first, then decide if it belongs on your watchlist
The PFE score, explanation, management facts, and filing sources are all here. When you want to follow more companies, review new-filing changes, or keep notes for the next review, keep more names in your watchlist.
Read the report first
Understand the company first. Keep up with every filing as your list grows.
A single report helps you judge one company. As your watchlist grows, review score, cash flow, moat, and risk changes together instead of repeating the same work.
Keep more names together
When your list grows, keep PFE with the rest of your names and review score, grade, and risk changes over time.
See how to track more namesAsk follow-up questions
Dig into cash conversion, moat evidence, capital allocation, and risk changes without rereading the full 10-K.
Ask a questionExport and revisit records
Save the PFE report as research notes you can revisit before the next filing.
Save research notesCore Dimension Scores
Evaluating competitive strength across earnings quality, moat strength, and risk sustainability
Overall Score Trend
Earnings Quality
71.9% gross margin — typical for branded pharma. Lower than MRK's 76% because Pfizer carries more small-molecule vs biologic mix and the Seagen ADC integration brings new COGS dynamics. Still elite sector-relative.
OCF of $12.7B against NI of $8.0B = 1.59x — elevated by Seagen amortization + integration charges suppressing GAAP NI. Cash-based earnings materially stronger than headline NI suggests.
Revenue of $63.6B in FY2024 vs FY2022 peak of ~$100B — the Covid runoff is now largely complete. Comirnaty + Paxlovid have stabilized at meaningful but much smaller levels; non-Covid business (Eliquis, Vyndaqel, Prevnar, oncology portfolio) is the growth base going forward.
12.5% net margin in FY2024 vs 31% at FY2022 peak. The compression reflects Covid-premium pricing absorbed + Seagen amortization charges + restructuring costs. Normalized margin (ex-one-time items) is closer to 18-20%.
Earnings quality scores 74/100. 1.59x CF/NI is the key signal — Seagen purchase-accounting amortization artificially suppresses reported NI, so cash earnings are significantly stronger than the 12.5% margin suggests. The Covid base normalization is now effectively complete; from FY2025, the YoY comparisons become cleaner. Underlying business quality is intact, the number is just clouded by integration noise.
Moat Strength
The $43B Seagen acquisition (closed Dec 2023) added Padcev (bladder cancer), Adcetris (lymphoma), Tivdak (cervical cancer), and the ADC technology platform. Pfizer's oncology revenue positioning jumps from mid-tier to potential top-3 globally by 2030. ADC is the hottest technology platform in pharma.
Prevnar franchise (pneumococcal, adults + pediatric) is a $6B+ annuity business. Comirnaty has stabilized at $5-6B annual revenue (down from Covid peak but recurring seasonal demand). Per the FY2024 10-K manufacturing and regulatory disclosures, vaccine-platform manufacturing capacity and regulatory qualifications form a durable barrier.
Eliquis (anticoagulant, partnered with BMS) is a $7B+ franchise; Vyndaqel (transthyretin amyloidosis) is ~$5B and growing with new approvals. These are cash cows with multi-year patent runway before 2028 generic entry considerations.
Pfizer's obesity program (danuglipron) was discontinued in 2023 after side-effect issues; a second-generation candidate remains in development but behind LLY/Novo. RSV vaccine (Abrysvo) launched but competitive with GSK's Arexvy. Pipeline depth is OK but no clear Keytruda-scale asset on the horizon.
Moat strength scores 76/100. Seagen is the strategic reset — Pfizer re-enters top-tier oncology with ADC platform + three on-market products. Prevnar + cardiovascular + Comirnaty provide three defensive annuity businesses. The one narrative gap is obesity (danuglipron failure) and the lack of a single massive growth franchise comparable to Keytruda or Lilly's tirzepatide. Durability is good; breakout upside depends on Seagen pipeline execution.
Capital Allocation
FCF of $9.8B = 15.4% FCF margin on $63.6B revenue. Compressed vs Covid-peak levels but adequate to cover $9.5B annual dividend obligation. Seagen debt paydown + dividend preservation is the current priority, limiting M&A firepower.
Debt ratio rose to 59% after $31B of new debt to finance Seagen. Leverage remains manageable but higher than pre-deal 45%. Management has committed to deleveraging via FCF application over 2024-2026.
Pfizer has raised dividends for 15+ consecutive years. Annual payout ~$9.5B — coverage at 1.03x FCF is tight but management has publicly committed to maintenance. This constrains other capital uses near-term.
Pfizer has taken significant restructuring charges through FY2024 to right-size headcount post-Covid-boom. These depress GAAP NI but are non-recurring cash + non-cash items. The restructuring is visible in the cash-flow statement.
Capital allocation scores 68/100. Near-term flexibility is constrained — dividend maintenance + Seagen debt paydown absorb most FCF. The $43B Seagen bet is the strategic capital move; returns depend entirely on integration execution. Per Pfizer's dividend-history disclosures, the company has maintained continuous dividend payments over many years; FY2024 coverage metrics in the cash flow statement suggest limited cushion for sustained adversity.
Key Risks
Per Pfizer's March 2023 Seagen acquisition press release, the $43B transaction is one of the larger pharma M&A deals on public record. Integration involves merging cultures (Seagen was Seattle-based, collaborative, smaller) with Pfizer's global scale. Synergy realization + pipeline advancement determine if the $43B compounds or impairs.
Eliquis (anticoagulant, Pfizer-BMS alliance) core patents expire 2026-2028. Per the 10-K Risk Factors, loss of exclusivity on these products exposes revenue to generic and biosimilar competition. Similar erosion profile to historical patent cliffs.
Pfizer discontinued its oral GLP-1 program (danuglipron) in 2023 after adverse-events signals. The obesity category is the largest pharma growth vector through 2030; Pfizer's absence is a strategic miss. Second-generation candidates are years behind LLY/Novo.
Comirnaty + Paxlovid now generate ~$10B combined but with high season-to-season volatility depending on strain evolution, vaccination rates, and government procurement. The base has stabilized but forecasting precision is low.
Risk profile scores 60/100 (higher = safer). Seagen integration is the dominant multi-year bet. Eliquis patent erosion is the predictable next cliff. Obesity-pipeline gap is a strategic hole that limits upside participation in pharma's biggest growth category. Covid base is stable but low-precision. The risk profile is elevated vs Merck; the FCF cushion is tighter.
Management
Ask about this section
Ask one question here. Keep digging when the issue needs more work.
This analysis is for educational purposes only and does not constitute investment advice.